Edition:
United Kingdom

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

4.32USD
15 Dec 2017
Change (% chg)

$-0.07 (-1.59%)
Prev Close
$4.39
Open
$4.38
Day's High
$4.44
Day's Low
$4.32
Volume
993,281
Avg. Vol
69,919
52-wk High
$6.63
52-wk Low
$4.18

Chart for

About

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses,... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $244.17
Shares Outstanding(Mil.): 47.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Chimerix reports Q3 loss of $0.37/shr

* Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Chimerix Inc files for mixed shelf of up to $250 million

* Files for mixed shelf of up to $250 million - SEC filing‍​ Source text : (http://bit.ly/2m8BtgL) Further company coverage:

08 Nov 2017

BRIEF-Chimerix Inc entered into agreement with Cowen and Co

* On November 8, 2017, co entered into an at market issuance, or ATM, sales agreement with Cowen and Company LLC - SEC filing​

08 Nov 2017

BRIEF-Chimerix Inc appoints Heather Knight-Trent vice president of regulatory affairs

* Chimerix appoints Heather Knight-Trent, PHARMD, as vice president of regulatory affairs Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Chimerix reports Q2 loss per share $0.36

* Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

07 Aug 2017

Competitors

Earnings vs. Estimates